imatinib stada 400 mg filmom obalené tablety
stada arzneimittel ag, nemecko - imatinib - 44 - cytostatica
prodigestan perorálny prášok
tekro, Česká republika - plv.
imatinib sandoz 100 mg
sandoz pharmaceuticals d.d., slovinsko - imatinib - 44 - cytostatica
imatinib sandoz 400 mg
sandoz pharmaceuticals d.d., slovinsko - imatinib - 44 - cytostatica
nibix 400 mg
adamed pharma s.a., poľsko - imatinib - 44 - cytostatica
nibix 100 mg
adamed pharma s.a., poľsko - imatinib - 44 - cytostatica
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfóm, mantle-cell - antineoplastické činidlá - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
imatinib grindeks 100 mg tvrdé kapsuly
as grindeks, lotyšsko - imatinib - 44 - cytostatica
scemblix
novartis europharm limited - asciminib hydrochloride - leukémia, myelogénna, chronická, bcr-abl pozitívna - antineoplastické činidlá - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.